Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
700 KRW
−32.88 B KRW
354.89 B KRW
28.17 M
About SK BIOPHARMACEUTICALS
Sector
CEO
Dong-Hoon Lee
Headquarters
Seongnam-si
Website
Founded
1993
ISIN
KR7326030004
FIGI
BBG00GK8B7Y9
SK Biopharmaceuticals Co., Ltd. engages in the research and development of new drugs and antibiotics. Its products include Senobamate, Other Clinical Tasks, and Research Services. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 326030 is 111,100 KRW — it has increased by 7.80% in the past 24 hours. Watch SK BIOPHARMACEUTICALS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange SK BIOPHARMACEUTICALS stocks are traded under the ticker 326030.
326030 stock has risen by 9.17% compared to the previous week, the month change is a 7.60% rise, over the last year SK BIOPHARMACEUTICALS has showed a 13.60% increase.
We've gathered analysts' opinions on SK BIOPHARMACEUTICALS future price: according to them, 326030 price has a max estimate of 150,000.00 KRW and a min estimate of 57,000.00 KRW. Watch 326030 chart and read a more detailed SK BIOPHARMACEUTICALS stock forecast: see what analysts think of SK BIOPHARMACEUTICALS and suggest that you do with its stocks.
326030 reached its all-time high on Jul 7, 2020 with the price of 269,500 KRW, and its all-time low was 50,900 KRW and was reached on Oct 13, 2022. View more price dynamics on 326030 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
326030 stock is 9.43% volatile and has beta coefficient of 0.72. Track SK BIOPHARMACEUTICALS stock price on the chart and check out the list of the most volatile stocks — is SK BIOPHARMACEUTICALS there?
Today SK BIOPHARMACEUTICALS has the market capitalization of 8.13 T, it has decreased by −1.69% over the last week.
Yes, you can track SK BIOPHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
SK BIOPHARMACEUTICALS is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
326030 earnings for the last quarter are 123.44 KRW per share, whereas the estimation was 123.44 KRW resulting in a 0.00% surprise. The estimated earnings for the next quarter are 67.49 KRW per share. See more details about SK BIOPHARMACEUTICALS earnings.
SK BIOPHARMACEUTICALS revenue for the last quarter amounts to 136.60 B KRW, despite the estimated figure of 131.49 B KRW. In the next quarter, revenue is expected to reach 149.79 B KRW.
326030 net income for the last quarter is 9.65 B KRW, while the quarter before that showed 28.14 B KRW of net income which accounts for −65.69% change. Track more SK BIOPHARMACEUTICALS financial stats to get the full picture.
No, 326030 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 273.00 employees. See our rating of the largest employees — is SK BIOPHARMACEUTICALS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SK BIOPHARMACEUTICALS EBITDA is 87.54 B KRW, and current EBITDA margin is −6.42%. See more stats in SK BIOPHARMACEUTICALS financial statements.
Like other stocks, 326030 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SK BIOPHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SK BIOPHARMACEUTICALS technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SK BIOPHARMACEUTICALS stock shows the buy signal. See more of SK BIOPHARMACEUTICALS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.